PJWCreative, Author at HighField Bio

May 28, 2025 in Publications

ASCO 2025 Abstract: First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.

PJWCreative 0 Like Post Comments Off

Click here

April 30, 2025 in Publications

AACR 2025 Poster: Myeloid cell targeted immune modulation in solid tumor and brain tumor patients: an analysis of NCTO5388487 phase 1 study data.

PJWCreative 0 Like Post Comments Off

Click here

April 7, 2025 in Press Release

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

PJWCreative 0 Like Post Comments Off

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting Topline data fr ...

January 13, 2025 in Press Release

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

PJWCreative 0 Like Post Comments Off

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases Research papers focused on the importance of LNP s ...

December 18, 2024 in Press Release

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

PJWCreative 0 Like Post Comments Off

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers A Phase 1 trial of HF50 to evaluate ...

September 18, 2024 in HighField in the News

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

PJWCreative 0 Like Post 0 Comment

Click here

September 17, 2024 in Publications

ESMO 2024 Poster: A phase 1 study of the Myeloid-derived suppressor cells modulator HF1K16 in refractory and metastatic cancer patients: preliminary efficacy and safety.

PJWCreative 0 Like Post Comments Off

Click here

September 16, 2024 in Press Release

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

PJWCreative 0 Like Post Comments Off

Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers The data from the ongoi ...

September 4, 2024 in Uncategorized

HighField Biopharmaceuticals Company Profile – 2024

PJWCreative 0 Like Post Comments Off

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers The company's groundbreaking immunoliposome, containin ...

September 3, 2024 in Press Release

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

PJWCreative 0 Like Post Comments Off

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers The company's groundbreaking immunoliposome, contain ...